Earningsreport
Q2/2024 6/30/2024 EPS 11.560 ZacksConsensus 8.930 ActVsEst 2.630 - Beat
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
| IMPACT SNAPSHOT | EVENT TIME: | REGN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
REGN alerts
REGN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
NEWS
NEWS
- NTLA's Q3 Earnings & Revenues Beat Estimates, Pipeline in Focus [Yahoo! Finance][Yahoo! Finance]
- OncoResponse reports data from Phase I solid tumour treatment trial [Yahoo! Finance][Yahoo! Finance]
- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $1,150.00 to $1,000.00. They now have an "outperform" rating on the stock.[MarketBeat]
- Is It Time to Buy October's Worst-Performing Nasdaq Stocks? [Yahoo! Finance][Yahoo! Finance]
- Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis[GlobeNewswire]
- More
REGN
SEC Filings
SEC Filings
- 11/5/24 - Form 4
- 11/1/24 - Form 144
- 10/31/24 - Form S-3ASR
- REGN's page on the SEC website
- More